Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS Mutant Non-Small Cell Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT05254184
What this trial is testing

KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 12
Testing effectiveness (Phase 2)Study completedNCT01833143
What this trial is testing

Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D

Who this might be right for
Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center 17
Early research (Phase 1)Looking for participantsNCT06586515
What this trial is testing

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Who this might be right for
Pancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerColorectal Cancer
Eli Lilly and Company 630
Early research (Phase 1)Looking for participantsNCT06625775
What this trial is testing

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Who this might be right for
Solid Tumor, AdultMetastatic Breast CancerAdvanced Breast Cancer+8 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) 392
Testing effectiveness (Phase 2)WithdrawnNCT03004105
What this trial is testing

MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Malignant Neoplasm of Respiratory and Intrathoracic Organ CarcinomaAdvanced Lung CancerRecurrent Nonsmall Cell Lung Cancer
M.D. Anderson Cancer Center
Large-scale testing (Phase 3)Looking for participantsNCT06119581
What this trial is testing

First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell LungNeoplasm Metastasis
Eli Lilly and Company 1,264
Early research (Phase 1)Ended earlyNCT04965818
What this trial is testing

Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

Who this might be right for
Advanced or Metastatic Solid Tumors Irrespective of Gene AlterationsNon-Small Cell Lung CancerKRAS Gene Mutation
Taiho Oncology, Inc. 38
Testing effectiveness (Phase 2)Ended earlyNCT03777124
What this trial is testing

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Who this might be right for
NSCLC Stage IVKRAS Gene MutationPD-1 Antibody+1 more
Jiangsu HengRui Medicine Co., Ltd. 25
Early research (Phase 1)Looking for participantsNCT06835569
What this trial is testing

Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

Who this might be right for
CancerPDAC - Pancreatic Ductal AdenocarcinomaNSCLC (Non-small Cell Lung Cancer)+2 more
Alterome Therapeutics, Inc. 448
Testing effectiveness (Phase 2)Active Not RecruitingNCT05074810
What this trial is testing

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

Who this might be right for
Non Small Cell Lung CancerKRAS Activating Mutation
Verastem, Inc. 153
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07294261
What this trial is testing

Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC

Who this might be right for
Local Advanced or Metastatic NSCLC
Sun Yat-sen University 69
Testing effectiveness (Phase 2)Looking for participantsNCT07629960
What this trial is testing

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Who this might be right for
Advanced Solid TumorNon-Small Cell Lung CancerColorectal Neoplasms+1 more
Blueprint Medicines Corporation 265
Testing effectiveness (Phase 2)UnknownNCT02450656
What this trial is testing

Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer

Who this might be right for
Colorectal NeoplasmsGastrointestinal NeoplasmsPancreatic Neoplasms+1 more
The Netherlands Cancer Institute 320
Early research (Phase 1)Ended earlyNCT04916236
What this trial is testing

Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers

Who this might be right for
Pancreatic CancerColorectal CancerNon-small Cell Lung Cancer+1 more
The Netherlands Cancer Institute 24
Early research (Phase 1)Ended earlyNCT02974725
What this trial is testing

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Who this might be right for
Non-Small Cell Lung CancerMelanoma
Novartis Pharmaceuticals 241
Testing effectiveness (Phase 2)UnknownNCT05451056
What this trial is testing

An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to Sotorasib

Who this might be right for
Non Small Cell Lung Cancer
Yonsei University 37
Testing effectiveness (Phase 2)Active Not RecruitingNCT04956640
What this trial is testing

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Who this might be right for
Carcinoma, Non-Small-Cell LungColorectal NeoplasmsEndometrial Neoplasms+3 more
Eli Lilly and Company 540
Testing effectiveness (Phase 2)Active Not RecruitingNCT03808558
What this trial is testing

Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas

Who this might be right for
KRAS Gene Mutation
David E Gerber 18
Early research (Phase 1)Study completedNCT04967079
What this trial is testing

Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients

Who this might be right for
Non Small Cell Lung Cancer
Shanghai Chest Hospital 33
Early research (Phase 1)Study completedNCT02022982
What this trial is testing

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Who this might be right for
KRAS Mutant Non-Small Cell Lung CancerSolid Tumors
Dana-Farber Cancer Institute 60
Next Page